Ansicht Scidel Pharma India Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
About Ansicht Scidel Pharma India
Ansicht Scidel Pharma India Private Limited (ASPIPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 04 August 2015 (Nine years and five months 28 days old ). Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Research & Development Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gaurav Nahar, Ajinkya Inamdar, Arati Inamdar, and One other member serve as directors at the Company.
Company Details
- Location
Pune, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U73100PN2015PTC156066
- Company No.
156066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Ansicht Scidel Pharma India?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Darshan Nahar  | Director | 04-Aug-2015 | Current |
| Gaurav Nahar | Director | 04-Aug-2015 | Current |
| Ajinkya Inamdar | Director | 04-Aug-2015 | Current |
| Arati Inamdar | Director | 04-Aug-2015 | Current |
Financial Performance of Ansicht Scidel Pharma India.
Ansicht Scidel Pharma India Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Ansicht Scidel Pharma India?
In 2017, Ansicht Scidel Pharma India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Abgenics Life Sciences Private LimitedGaurav Nahar is a mutual person
Defiant Renewables Private LimitedGaurav Nahar and Darshan Nahar are mutual person
Defiant Energy Private LimitedGaurav Nahar and Darshan Nahar are mutual person
- Saiseva Biotech Private Limited
Gaurav Nahar and Arati Inamdar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ansicht Scidel Pharma India?
Unlock and access historical data on people associated with Ansicht Scidel Pharma India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ansicht Scidel Pharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ansicht Scidel Pharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
